Glembatumumab vedotin shows an novel strategy in cancer management. This ADC carefully targets an receptor found on multiple malignant cells, transporting an effective anti-cancer drug. Initial clinical trials demonstrate substantial response against particular hematological malignancies and are now being assessed for their possibility in managing